ORIGINAL ARTICLE

Revised: 31 August 2021



Preoperative neutrophil-to-lymphocyte ratio predicts healing time for postoperative pancreatic fistula after distal pancreatectomy

Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan

Correspondence

Shogo Kobayashi, Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2-E2, Yamadaoka, Suita, Osaka 565-0871, Japan.

Email: skobayashi@gesurg.med.osaka-u.ac.jp

Abstract

Purpose: Postoperative pancreatic fistula is a serious complication of distal pancreatectomy. Although many studies have described the incidence and risk factors associated with postoperative pancreatic fistula (POPF), few have focused on the healing time. This study investigated the healing time and potential factors associated with the healing time of POPF after distal pancreatectomy (DP).

Methods: Among 114 patients that underwent DP in our hospital from January 2010 to December 2020, we included 88 that developed POPF. The healing time for a postoperative pancreatic fistula was defined as the interval between the completion of DP and the removal of all drains related to the treatment for POPF. Based on the definition, three cases who required additional treatment after removal of all drains were excluded from this study. Clinical factors associated with the fistula healing times were investigated in the 85 patients.

Results: The average POPF healing time was 11 ± 10 days (median: 6 days, range: 3-57). We found that the neutrophil-to-lymphocyte ratio, a marker of inflammatory and nutritional status, was the only factor independently associated with the POPF healing time; the mean healing time was significantly shorter in patients with neutrophil-to-lymphocyte ratio <2.1 (8 ± 6 days) than in those with neutrophil-to-lymphocyte ratio >2.1 (13 ± 12 days; P = .0139).

Conclusion: We demonstrated that the neutrophil-to-lymphocyte ratio could independently predict the POPF healing time after DP. These findings suggested that improving the neutrophil-to-lymphocyte ratio might shorten the healing times for POPF after DP.

KEYWORDS

distal pancreatectomy, lymphocyte, neutrophil, neutrophil-to-lymphocyte ratio, pancreatic fistula

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. © 2021 The Authors. *Annals of Gastroenterological Surgery* published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterological Surgery.

1 | INTRODUCTION

Distal pancreatectomy (DP) is the curative treatment for various diseases that occur in the body and/or tail of the pancreas. Improvements in surgical techniques and perioperative management have reduced the incidences of postoperative morbidity and mortality after pancreatectomy. However, postoperative pancreatic fistula (POPF) remains one of the most common complications of DP; the incidence is approximately 10%-40%.¹⁻³ Once POPF develops, it can trigger subsequent postoperative complications, such as intra-abdominal abscess and pseudoaneurysm associated with postpancreatectomy hemorrhage. These complications can potentially extend postoperative hospitalization, increase the treatment costs. and even lead to postoperative mortality. In this context, many investigators have identified factors predictive of the risk of developing POPF, such as obesity, nutritional status, pancreas thickness. and pancreas consistency.⁴⁻⁷ Thus, predicting the risk of developing POPF has been established for patients that require DP. However, POPF continue to develop, despite the prediction. Therefore, it is important to select the appropriate POPF treatment. Although the choice of a therapeutic option plays a role in the POPF treatment, it is also important to estimate how long it might take to achieve a complete cure. To that end, we previously investigated the time needed to cure POPF after pancreaticoduodenectomy.^{8,9} However, to date, few studies have investigated the time necessary for POPF to heal after DP.¹⁰

-WILEY- AGSurg Annals of Gastroenterological Surgery

Recent studies have focused on whether the inflammatory and nutritional status of patients might potentially influence wound healing, the risk of postoperative complications, and even a cancer prognosis.¹⁰⁻¹⁵ Additionally, several studies have reported a significant association between nutritional status and the incidence of POPF.^{3,5,16,17} Considering that inflammatory and nutritional status is associated with wound healing, we reasoned that these statuses might also affect the time for POPF to heal.

Based on this background, in the present study, we aimed to assess the time needed to cure POPF after DP. Moreover, we evaluated whether factors associated with inflammatory and nutritional statuses might affect the POPF healing time.

2 | PATIENTS AND METHODS

A total of 149 consecutive patients underwent DP, from January 2010 to December 2020, in the Department of Gastroenterological Surgery, Osaka University Hospital. Among the 149 patients, 35 were excluded from this retrospective study, because they required resections of other organs, in addition to DP (21 cases), or they underwent other procedures for treating the pancreatic stump, including DP with hand-sewn stump closure (three cases) and anastomosis with intestinal tract (11 cases). Among the remaining 114 patients, 88 (77.2%) developed POPF. In the 88 patients, three cases, who required additional treatment after removal of all drainage tubes, were excluded from this study based on the

definition of the POPF healing time described below. Finally, 85 patients were included in the present study. The clinical and surgical characteristics of the patients are summarized in Table 1. Furthermore, in the 85 patients, we investigated factors that might affect the POPF healing time.

In this study, the POPF healing time was defined as the interval from the day of DP to the day when POPF was cured. The day of POPF cure was defined as the day that all intra-abdominal drainage tubes related to the treatment were removed.

We used the following factors to evaluate inflammatory and nutritional statuses in this study: white blood cell, neutrophil, lymphocyte, and platelet counts; albumin, total cholesterol, and C-reactive protein (CRP) levels; the prognostic nutritional index (PNI), the controlling nutritional status (CONUT); the neutrophil-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR), and the modified Glasgow prognosis score (mGPS).¹⁸⁻²¹

Distal pancreatectomy was performed with a triple-row linear stapler, and the closure jaw was clamped carefully and slowly, at a fixed speed, over a period of at least 5 minutes.²² Prior to the completion of pancreatic surgery, an intra-abdominal, closed-suction drainage tube was placed near the pancreas stump. In patients that also underwent spleen removal, another tube was placed at the left subphrenic space.

The POPF diagnosis was based on the definition established by the International Study Group of Pancreatic Fistula (ISGPF),¹⁰ with the following severity grades: biochemical leakage (BL), grade B, and grade C. All patients received the same postoperative management, including the POPF treatment. Briefly, we measured the amylase concentration in the drainage fluid on the first and third postoperative days. In patients that developed POPF, octreotide was administered when the amylase concentration in the drainage fluid was >5000 U/L. The intra-abdominal drainage tube was changed every 1-2 weeks, and the drainage tube was removed when the patients were asymptomatic and imaging modalities confirmed the disappearance of the intra-abdominal cavity independently of appearance or amylase concentration in the drainage fluid through the tubes. The main pancreatic duct diameter was measured at the resection line of the pancreas on enhanced computed tomography images.

Data are described as the mean \pm standard deviation for continuous variables and the number for categorical variables. Betweengroup differences were assessed with the Mann-Whitney *U*-test, the chi-square test, and Fisher's exact test, as appropriate. The POPF healing time was estimated with the Kaplan-Meier method, and cumulative POPF healing rates were compared between groups with the log-rank test. Cox proportional hazards models were constructed for multivariate analyses to identify independent variables that significantly affected the POPF healing time. Continuous variables were converted to categorical variables by forming groups above and below the median value for each variable. We determined the odds ratio (OR) and 95% confidence interval (CI) for each variable. Statistical analyses were performed with the JMP[®] software program (SAS Inc.). *P* values <.05 were considered statistically significant. After an extensive dialogue with the Institutional Ethics Review Committee, patient consent for participation was obtained through an opt-out method. The present study was approved by the Institutional Ethics Review Committee (Certificate Number 20466).

TABLE 1 Perioperative characteristics of 85 individuals with POPF

Characteristic	Measurement				
Preoperative factors					
Age (years)	59 ± 18				
Sex (Male/Female)	39/46				
Height (cm)	160.9 ± 9.3				
Weight (kg)	57.0 ± 11.1				
BMI (kg/m²)	22.0 ± 3.6				
Disease (Pancreatic cancer/Others)	35/40				
Neoadjuvant therapy (no/yes)	69/16				
White blood cells (/µL)	5185 ± 1539				
Neutrophils (g/dL)	3084 ± 1113				
Lymphocytes (/µL)	1515 ± 660				
Platelets ($10^4/\mu L$)	26.5 ± 16.2				
Albumin (g/dL)	4.0 ± 0.4				
Total cholesterol (mg/dL)	188 ± 38				
CRP (mg/dL)	0.16 ± 0.36				
PNI	40.2 ± 3.6				
NLR	2.4 ± 1.3				
PLR	214.0 ± 203.9				
mGPS (0/1/2)	77/8/0				
CONUT (0-1/2-4/5-8/9-12)	37/37/11/0				
MPD diameter (mm)	2.3 ± 2.0				
Pancreas thickness (mm)	10.9 ± 3.3				
Intraoperative factors					
Surgical approach (Open/Laparoscopic)	62/23				
Position of pancreas dissection (Portal vein/ Body, Tail)	56/29				
Operation time (min)	267 <u>±</u> 86				
Intraoperative blood loss (mL)	293 <u>+</u> 355				
Spleen preservation (no/yes)	74/11				
Postoperative factors					
POPF (BL/Grade B/Grade C)	60/25/0				
Amylase concentration in the drainage fluid (U/L)					
on POD1	7007 ± 8149				
on POD3	8781 ± 48 539				
Administration of octreotide (\mp)	59/26				

Note: Data are expressed as the mean \pm standard deviation, for continuous variables, or the number of patients, for categorical variables.

Abbreviations: BL, biochemical leakage; BMI, body mass index; CONUT, controlling nutritional status; CRP, C-reactive protein; mGPS, modified Glasgow prognosis score; MPD, main pancreatic duct; NLR, neutrophilto-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; POD, postoperative day; POPF, postoperative pancreatic fistula. AGSurg Annals of Gastroenterological Surgery

3 | RESULTS

Among the 114 patients that underwent DP, 88 (77.2%) developed POPF. Of the 88 patients, three patients were excluded from this study, as they required additional treatment after removal of all drainage tubes. Among the 85 patients, the POPF severity grades were BL (n = 60) and grade B (n = 25); no patient exhibited grade C POPF. No patients were discharged from the hospital or died after surgery before the POPF was cured. Patient characteristics are shown in Table 1.

The average POPF healing time was 11 \pm 10 days (median, 6 days; range 3-57). Individual POPF healing times are shown in Figure 1. The POPF healing time was significantly longer in patients with grade B than in those with BL (22 \pm 11 days vs 6 \pm 2 days; *P* < .001). The cumulative POPF healing rates were calculated with




FIGURE 1 Individual POPF healing times. Each bar indicates the number of patients that experienced the indicated POPF healing time. POPF, postoperative pancreatic fistula




FIGURE 2 Cumulative POPF healing rate in patients, stratified by the POPF grade, defined by the ISGPF. The cumulative POPF healing rate was calculated with the Kaplan-Meier method. The healing time was significantly shorter in patients with BL than in patients with grade B (P < .0001). BL, biochemical leak; ISGPF, International Study Group of Pancreatic Fistula; POPF, postoperative pancreatic fistula

the Kaplan-Meier method (Figure 2). This result was consistent with the definition of POPF^{10}

To investigate which factors could significantly determine the POPF healing time, we performed a univariate analysis of potentially influential factors (Table 2). In this analysis, we only included factors that were clearly known prior to surgery to establish a predictive model with preoperative factors. The univariate analysis showed that the NLR and body weight were significantly related to the POPF healing time. Patients with NLR \leq 2.1 had significantly shorter POPF healing times than those with NLR >2.1 (healing times: 8 ± 6 days vs 13 ± 12 days; *P* = .0139). Patients with body weights \leq 56.0 kg also had significantly shorter POPF healing times than those with body weights >56.0 kg (healing times: 8 ± 7 days vs 13 ± 12 days; *P* = .0341). The univariate analysis also identified one marginally

TABLE 2	Univariate and multivariate analysis results for POP	F healing times among patients that	underwent a distal pancreatectomy
---------	--	-------------------------------------	-----------------------------------

Factors Number OR 95% Cl Pvalue OR 95% Cl Pvalue Preoperative factors			Univariate		Multivariate			
Age (years) (263 vs > 63) 41/44 1.0414 0.67621.6040 .8411 Sex (Male vs Female) 39/46 0.7272 0.4676-1.1310 1.216 Height (kg) (516 vs >50) 43/42 1.2765 0.8191-1.9840 .5567 Weight (kg) (516 vs >50) 44/41 1.2764 0.8331-1.664 .225 .0870 BMI (kg/m ²) (51 vs >21) 44/41 1.2764 0.8331-1.664 .225 .0870 Necadiuant therapy (no vs yes) 69/16 0.6115 0.3497-1.0691 .0555 .0870 White blood cells (/µL) 43/42 0.9389 0.60681-4528 .7575 .757 Neutrophik (g/l1) 42/43 1.3373 0.8657-2.0656 .1522	Factors	Number	OR	95% CI	P value	OR	95% CI	P value
Sex (Male vs Female) 39/46 0.7272 0.4676-1.1310 .1216 Height (cm) (s162 vs >162) 43/42 1.2765 0.8191-19840 .5567 Weight (kg) (s56 vs >56) 44/41 1.5390 0.9924-2.3867 .0341 1.4696 0.9456-2.2839 .0670 BMI (kg/m) (s21 vs >21) 44/41 1.2784 0.8303.1/684 .2235	Preoperative factors							
Height (m) (s162 vs >162) 43/42 1.2765 0.81911.9840 .5567 Weight (kg) (s56 vs >56) 44/41 1.5390 0.9924-2.3867 .0341 1.4696 0.9456-2.2839 .0870 BM (kg/m²) (s21 vs >21) 44/41 1.2784 0.8303-1.9684 .2235	Age (years) (≤63 vs >63)	41/44	1.0414	0.6762-1.6040	.8411			
Weight (kg) (s56 vs >56) 44/41 1.5390 0.9924-2.3867 0.341 1.4696 0.9456-2.2839 0.870 BMI (kg/m ³) (s21 vs >21) 44/41 1.2784 0.8303-1.9684 .2235	Sex (Male vs Female)	39/46	0.7272	0.4676-1.1310	.1216			
BM (kg/m ²) (s21 vs >21) 44/41 1.2784 0.83031.9684 .2235 Disease (Pancreatic cancer vs Others) 39/46 0.7841 0.50371.2204 .2386 Necadjuvant therapy (no vs yes) 69/16 0.6115 0.34971.10691 .0555 White blood cells (/µL) (s2893 vs >2893) 1.3373 0.8657.2.0656 .1522 Lymphocytes (/µL) (s2893 vs >2893) 42/43 0.8104 0.52691.2463 .2964 Albumin (g/qL) (s4.0 vs >4.0) 42/43 0.8104 0.52691.2463 .2964 Albumin (g/qL) (s4.0 vs >4.0) 45/40 0.9628 0.6256.1.4817 .8511 CRP (mg/qL) (s0.04 vs >0.04) 48/37 1.3054 0.8441.2.0187 .1911 Total cholesterol (mg/qL) (s190 vs >160) 44/41 0.9552 0.6187.1.4749 .8218 PNI (s40.1 vs >40.1) 43/42 0.9897 0.6444.1.5197 .9588 NLR (s21 vs >21) 41/44 1.6685 1.0613.2.6232 .0139 1.5995 1.0167.2.5164 .0422 PR (s160.7 vs 160.7) 42/43 0.9141 0.5707.1.4145 .6600 <td>Height (cm) (≤162 vs >162)</td> <td>43/42</td> <td>1.2765</td> <td>0.8191-1.9840</td> <td>.5567</td> <td></td> <td></td> <td></td>	Height (cm) (≤162 vs >162)	43/42	1.2765	0.8191-1.9840	.5567			
Disease (Pancreatic cancer vs Others) 39/46 0.7841 0.5037-1.2204 .2386 Neoadjuvant therapy (no vs yes) 69/16 0.6115 0.3497-1.0691 .0555 White blood cells (/µL) (s4960 vs >4960) 43/42 0.9389 0.60681.4528 .7575 Neutrophils (g/d1) (s2893 vs >2893) 42/43 1.3373 0.8657-2.0656 1522 Lymphocytes (/µL) (s1379 vs >13379) 42/43 0.8104 0.5269-1.2463 .2964 Albumin (g/d1) (s0.04 vs >40.0) 45/40 0.9628 0.6256-1.4817 .8511 CRP (mg/d1) (s0.04 vs >0.04) 48/37 1.3054 0.8441-2.0187 1911 Total cholesterol (mg/d1) 43/42 0.9897 0.64187-1.4749 .8218 NIK (s2.1 vs >2.1) 41/44 1.6685 1.0613-2.6222 .0139 1.0167-2.5164 .0422 PR (s160.7) vs :160.7) 42/43 0.9947 0.6434-1.5197 .9588	Weight (kg) (≤56 vs >56)	44/41	1.5390	0.9924-2.3867	.0341	1.4696	0.9456-2.2839	.0870
vs Others) Neoadjuvant therapy (no vs yes) 6/16 0.6115 0.34971.0691 .0555 White blood cells (/µL) (st980 vs >4960) 3/42 0.9392 0.6061.4528 .755 Neutrophils (g/dL) (st980 vs >2983) 2/43 1.3373 0.8657-2.0556 1.522 Lymphocytes (/µL) (st979 vs >1377) 2/43 0.8669 0.5603-1.3412 .4836 Platelets (10 ⁴)/µL) (st2.0 vs >2.00 42/43 0.8104 0.5269-1.2463 .2964 Albumin (g/dL) (st0.0 vs >0.01 45/40 0.9228 0.6256-1.4817 .5511 Total cholestrol (mg/dL) (st190 vs >100) 45/40 0.9262 0.6187-1.4749 .5218 PNI (st0.1 vs >40.1) 43/42 0.9877 0.6441-1517 .5818 NLR (st2.1 vs >2.1) 41/44 1.6665 1.0613-2.532 .1595 1.0167-2.5164 .0422 PNI (st0.1 vs >40.1) 43/42 0.9974 0.6441-1.517 .5818	BMI (kg/m²) (≤21 vs >21)	44/41	1.2784	0.8303-1.9684	.2235			
White blood cells (v1, v1, v2, v2, v3, v3, v3, v3, v3, v3, v3, v3, v3, v3		39/46	0.7841	0.5037-1.2204	.2386			
(49400 vs >4950)Neutrophils (g/d1) (s2893 vs >2893)42/431.33730.8657-2.06561.522Lymphocytes (µ1) (s1379 vs >1379)42/430.86690.5603-1.34124836Platelets (10 ⁴ /µ1) (s22.0 vs >22.0)42/430.81040.5269-1.2463.2964Albumin (g/d1) (s4.0 vs >4.0)45/400.96280.625.6-1.4817.8511CRP (mg/d1) (s0.0 vs >0.04)48/371.30540.8441-2.0187.1911Total cholesterol (mg/d1) (s100 vs >100)44/410.95520.6187-1.4749.8218PNI (s40.1 vs >40.1)43/420.99770.6444-1.5197.9588NLR (s2.1 vs >2.1)41/441.66851.0613-2.6232.01391.59951.0167-2.5164.0422PRI (s40.7 vs ≥160.7)42/430.91410.5907-1.4145.6600.6609.6604.5766.9012PGS (0 vs 1 or 2)77/81.0940.5273-2.2923.7840.7840.7840.7840CONUT (0 or 1 vs >1.9)37/480.97620.6304-1.5117.9064Pance as thickness (mm) (s10 4 vs >10.4).6143.0669-1.5766.9012Pance as thickness (mm) (s10 4 vs >10.4).61/240.7642.65301-1.3139.3935Position of pancreas dissection (Open-Laparoscopic).61/20.9156.5301-1.3139.3935Position of pancreas dissection (s244 vs >244).63/4.0108.5301-1.3139.3935Position of pancreas dissection (s244 vs >244).61/4.0108.5301-1.3139<	Neoadjuvant therapy (no vs yes)	69/16	0.6115	0.3497-1.0691	.0555			
(s2893 vs > 2893) 42/43 0.8669 0.5603-1.3412 .4836 (s1379 vs > 1379) 42/43 0.8104 0.5269-1.2463 .2964 Albumin (g/dL) (s2.2 vs > 22.0) 42/43 0.8104 0.6256-1.2463 .2964 Albumin (g/dL) (s4.0 vs > 4.0) 45/40 0.9628 0.6256-1.2463 .1911 Total cholesterol (mg/dL) (s0.04 vs > 0.04) 48/37 1.3054 0.8441-2.0187 .1911 Total cholesterol (mg/dL) (s4.0 vs > 4.0.) 43/42 0.9897 0.6444-1.5197 .9588 NLR (s2.1 vs > 2.1) 41/44 1.6685 1.0613-2.6232 .0139 1.5995 1.0167-2.5164 .0422 PLR (s160.7 vs ≥160.7) 42/43 0.9141 0.5207 3.22923 .7860		43/42	0.9389	0.6068-1.4528	.7575			
		42/43	1.3373	0.8657-2.0656	.1522			
Albumin (g/dL) ($\leq4.0 ext{ vs } > 4.0$)45/400.96280.6256-1.4817.8511CRP (mg/dL) ($\leq0.04 ext{ vs } > 0.04$)48/371.30540.8441-2.0187.1911Total cholesterol (mg/dL) ($\leq190 ext{ vs } > 100$)44/410.95520.6187-1.4749.8218PNI ($\leq40.1 ext{ vs } > 40.1$)43/420.98970.6444-1.5197.9588NLR ($\leq2.1 ext{ vs } > 2.1$)41/441.66851.0613-2.6232.01391.59951.0167-2.5164.0422PLR ($\leq160.7 ext{ vs } \geq 160.7$)42/430.91410.5907-1.4145.6600		42/43	0.8669	0.5603-1.3412	.4836			
$\begin{array}{ c c c } CRP (m_{c}Ll) (s0.04 vs > 0.04) & 48/37 & 1.3054 & 0.8441-2.0187 & 1911 \\ \hline CRP (m_{c}Ll) (s0.04 vs > 0.04) & 48/37 & 1.3054 & 0.8441-2.0187 & 1911 \\ \hline Total cholesterol (mg/dL) & 44/41 & 0.9552 & 0.6187-1.4749 & 8218 \\ \hline PNI (s40.1 vs > 40.1) & 43/42 & 0.9897 & 0.64441.5197 & .9588 \\ \hline NLR (s2.1 vs > 2.1) & 41/44 & 1.6685 & 1.0613-2.6232 & .0139 & 1.5995 & 1.0167-2.5164 & .0422 \\ \hline PLR (s160.7 vs \ge 160.7) & 42/43 & 0.9141 & 0.5907-1.4145 & .6600 \\ \hline mGPS (0 vs 1 or 2) & 77/8 & 1.0994 & 0.5273-2.2923 & .7840 \\ \hline CONUT (0 or 1 vs 2-12) & 37/48 & 0.9762 & 0.6304-1.5117 & .9064 \\ \hline MPD diameter (mm) (s1.9 vs > 1.9) & 44/41 & 1.0254 & 0.6669-1.5766 & .9012 \\ \hline Pancreas thickness (mm) & 46/39 & 1.1731 & 0.7611-1.8079 & .4304 \\ \hline Intraoperative factors & & & & & & & & & & & & & & & & & & &$	Platelets (10 ⁴ /µL) (≤22.0 vs >22.0)	42/43	0.8104	0.5269-1.2463	.2964			
Total cholesterol (mg/dL) (≤190 vs >190)44/410.95520.6187-1.4749.8218PNI (≤40.1 vs >40.1)43/420.98970.6444-1.5197.9588NLR (≤2.1 vs >2.1)41/441.66851.0613-2.6232.01391.59951.0167-2.5164.0422PLR (≤160.7 vs ≥160.7)42/430.91410.5907-1.4145.6600	Albumin (g/dL) (≤4.0 vs >4.0)	45/40	0.9628	0.6256-1.4817	.8511			
$ \begin{array}{ c c c c c } (<190 \text{ vs } >190 & \\ \hline c c c c c c c c c c c c c c c c c c c$	CRP (mg/dL) (≤0.04 vs >0.04)	48/37	1.3054	0.8441-2.0187	.1911			
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$		44/41	0.9552	0.6187-1.4749	.8218			
PLR (≤ 160.7 vs ≥ 160.7)42/430.91410.5907-1.4145.6600mGPS (0 vs 1 or 2)77/81.09940.5273-2.2923.7840CONUT (0 or 1 vs 2-12)37/480.97620.6304-1.5117.9064MPD diameter (mm) (≤ 1.9 vs >1.9)44/411.02540.6669-1.5766.9012Pancreas thickness (mm) (≤ 10.4 vs >10.4)46/391.17310.7611-1.8079.4304Intraoperative factorsSurgical approach (Open/Laparoscopic)61/240.74620.4571-1.2183.1947Operation of pancreas dissection (≤ 244 vs >244)56/290.83460.5301-1.3139.3935Operation time (min) (≤ 244 vs >244)41/411.10180.7161-1.6953.6311	PNI (≤40.1 vs >40.1)	43/42	0.9897	0.6444-1.5197	.9588			
mGPS (0 vs 1 or 2) 77/8 1.0994 0.5273-2.2923 .7840 CONUT (0 or 1 vs 2-12) 37/48 0.9762 0.6304-1.5117 .9064 MPD diameter (mm) (s1.9 vs >1.9) 44/41 1.0254 0.6669-1.5766 .9012 Pancreas thickness (mm) (s10.4 vs >10.4) 46/39 1.1731 0.7611-1.8079 .4304 Intraoperative factors 50/2 0.4571-1.2183 .1947 Surgical approach (Open/Laparoscopic) 61/24 0.7462 0.4571-1.2183 .1947 Operation of pancreas dissection (Portal vein/Body, Tail) 56/29 0.8346 0.5301-1.3139 .3935 Operation time (min) (s2244 vs >244) 43/42 0.9156 0.5958-1.4069 .6614 Intraoperative blood loss (mL) (s170 vs >170) 44/41 1.1018 0.7161-1.6953 .6311	NLR (≤2.1 vs >2.1)	41/44	1.6685	1.0613-2.6232	.0139	1.5995	1.0167-2.5164	.0422
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	PLR (≤160.7 vs ≥160.7)	42/43	0.9141	0.5907-1.4145	.6600			
MPD diameter (mm) ($\leq 1.9 \text{ vs } > 1.9$)44/411.02540.6669-1.5766.9012Pancreas thickness (mm) ($\leq 10.4 \text{ vs } > 10.4$)46/391.17310.7611-1.8079.4304Intraoperative factorsSurgical approach (Open/Laparoscopic)61/240.74620.4571-1.2183.1947Position of pancreas dissection (Portal vein/Body, Tail)56/290.83460.5301-1.3139.3935Operation time (min) ($\leq 244 \text{ vs } > 244$)43/420.91560.5958-1.4069.6614Intraoperative blood loss (mL) ($\leq 170 \text{ vs } > 170$)44/411.10180.7161-1.6953.6311	mGPS (0 vs 1 or 2)	77/8	1.0994	0.5273-2.2923	.7840			
Pancreas thickness (mm) ($\leq 10.4 \text{ vs} > 10.4$)46/391.17310.7611-1.8079.4304Intraoperative factorsSurgical approach (Open/Laparoscopic)61/240.74620.4571-1.2183.1947Position of pancreas dissection (Portal vein/Body, Tail)56/290.83460.5301-1.3139.3935Operation time (min) ($\leq 244 \text{ vs} > 244$)43/420.91560.5958-1.4069.6614Intraoperative blood loss (mL) ($\leq 170 \text{ vs} > 170$)44/411.10180.7161-1.6953.6311	CONUT (0 or 1 vs 2-12)	37/48	0.9762	0.6304-1.5117	.9064			
$(\le 10.4 \text{ vs} > 10.4)$ Intraoperative factors $\begin{array}{c c c c c c c c c c c c c c c c c c c $	MPD diameter (mm) (≤1.9 vs >1.9)	44/41	1.0254	0.6669-1.5766	.9012			
Surgical approach (Open/Laparoscopic) $61/24$ 0.7462 $0.4571-1.2183$ $.1947$ Position of pancreas dissection (Portal vein/Body, Tail) $56/29$ 0.8346 $0.5301-1.3139$ $.3935$ Operation time (min) (≤ 244 vs > 244) $43/42$ 0.9156 $0.5958-1.4069$ $.6614$ Intraoperative blood loss (mL) (≤ 170 vs > 170) $44/41$ 1.1018 $0.7161-1.6953$ $.6311$		46/39	1.1731	0.7611-1.8079	.4304			
(Open/Laparoscopic) Position of pancreas dissection (Portal vein/Body, Tail) 56/29 0.8346 0.5301-1.3139 .3935 Operation time (min) (≤244 vs >244) 43/42 0.9156 0.5958-1.4069 .6614 Intraoperative blood loss (mL) (≤170 vs >170) 44/41 1.1018 0.7161-1.6953 .6311	Intraoperative factors							
(Portal vein/Body, Tail) Operation time (min) 43/42 0.9156 0.5958-1.4069 .6614 (≤244 vs >244) Intraoperative blood loss (mL) 44/41 1.1018 0.7161-1.6953 .6311 (≤170 vs >170) 		61/24	0.7462	0.4571-1.2183	.1947			
(≤244 vs >244) Intraoperative blood loss (mL) 44/41 1.1018 0.7161-1.6953 .6311 (≤170 vs >170)		56/29	0.8346	0.5301-1.3139	.3935			
(≤170 vs >170)		43/42	0.9156	0.5958-1.4069	.6614			
Spleen preservation (∓) 74/11 0.5791 0.3014-1.1120 .0641	•	44/41	1.1018	0.7161-1.6953	.6311			
	Spleen preservation (\mp)	74/11	0.5791	0.3014-1.1120	.0641			

Abbreviations: 95% CI, 95% confidence interval; BL, biochemical leakage; BMI, body mass index; CONUT, controlling nutritional status; CRP, Creactive protein; mGPS, modified Glasgow prognosis score; MPD, main pancreatic duct; NLR, neutrophil-to-lymphocyte ratio; OR, odds ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; POD, postoperative day; POPF, postoperative pancreatic fistula. significant factor: the presence/absence of neoadjuvant therapy. The average POPF healing times were 8 ± 5 days in patients that received neoadjuvant therapy and 11 ± 10 days in the group without neoadjuvant therapy (P = .0555). On the other hand, no significant associations with the POPF healing time were found for age, sex, height, disease, white blood cells, neutrophils, lymphocytes, platelets, albumin, CRP, total cholesterol, PNI, PLR, mGPS, CONUT, the main pancreatic duct diameter, or pancreas thickness.

Next, to identify independent factors that significantly affected the POPF healing time, we performed a multivariate analysis of the two factors that showed significance in the univariate analyses, NLR and body weight. The multivariate analysis showed that NLR was the only independently significant factor for POPF healing time (OR: 1.5995, 95% Cl: 1.02-2.51, P = .0422). Body weight was a marginally significant factor for POPF healing time (OR: 1.4696, 95% Cl: 0.95-2.28, P = .0870). We also performed a univariate analysis of potentially influential intraoperative factors on the POPF healing time, including surgical approach, position of pancreas dissection, operation time, intraoperative blood loss, and presence/absence of spleen preservation. However, while the presence/absence of spleen preservation was marginally significant, the other factors were not significantly associated with the POPF healing time.

Based on these results, we performed a Kaplan-Meier analysis to calculate the cumulative POPF healing rates for patients with NLR values above and below the median value (Figure 3). The cumulative rate for the NLR \leq 2.1 group was significantly higher than that of the NLR >2.1 group (*P* = .0139). This trend was confirmed in cases with patients with grade B POPF (healing times: NLR \leq 2.1 group; 17 \pm 8 days vs NLR >2.1 group; 24 \pm 12 days) (OR: 2.1858, 95% CI: 0.88-5.46, *P* = .0776), while those with BL POPF did not exhibit the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days vs NLR >2.1 group; 6 \pm 2 days vs NLR >2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (healing times: NLR \leq 2.1 group; 6 \pm 2 days of the trend (h




FIGURE 3 Cumulative POPF healing rate in patients, stratified by the NLR. The cumulative POPF healing rate was calculated with the Kaplan-Meier method. The healing time was significantly shorter for patients with NLR \leq 2.1 than for patients with NLR >2.1 (P = .0139). NLR, neutrophil-to-lymphocyte ratio; POPF, postoperative pancreatic fistula

factors that determine the ISGPF grade, was observed significantly more frequently in the NLR >2.1 group (10/44 patients; 22.7%) than in the NLR \leq 2.1 group (3/41 patients; 7.3%; P = .0431).¹⁰

4 | DISCUSSION

Postoperative pancreatic fistula is one of the most important postoperative complications of DP, and it is associated with secondary postoperative complications. Most previous studies have focused on the incidence of POPF and factors associated with POPF development.¹⁻³ From the clinical point of view, it is also important to know how long it takes to completely cure POPF after it develops. In this context, this study investigated the POPF healing time after DP. Furthermore, we investigated inflammatory and nutritional status markers, based on previous reports that showed a relationship between nutritional status and wound healing.^{11,23,24} Our results demonstrated that NLR was the only independent factor that could predict the POPF healing time. Unfortunately, it remains unclear why NLR was the independent factor predictive of the POPF healing time. In general, good inflammatory and nutritional status have been reported to be one of the important factors in wound healing.^{11,23,24} Furthermore, it would be expected that the healing capacity is potentially associated with the POPF cure. We speculate that these may have caused the significant association between lower NLR and the shorter healing time. The present study implemented two novel approaches that improved the interpretation of our results in the context of managing patients that plan to receive DP. First, to the best of our knowledge, no previous study has investigated the healing time of all POPF after DP. Although Andrianello et al²⁵ investigated the POPF healing time after DP, they included only patients with grade B/C POPF; in contrast, the present study also included patients with BL POPF. Based on the ISGPF definition of POPF, BL and grade B/C are determined during the postoperative course, because on postoperative day 3, when POPF development is evaluated based on the fluid amylase level, in most cases, it is not possible to differentiate the grade. Nevertheless, for predicting the healing time, it is desirable to include both grade B/C and BL in the analyses. Thus, our study approach was more informative than the approach used previously by Andrianello et al. Second, in the cohort studied by Andrianello et al, 24.8% of patients had been discharged with a drain. That feature could potentially make it difficult to calculate the healing time, because the removal of the last drain, which was used in the healing time calculation, might have been based on the patients' visits to the hospital, rather than the status of the wound. Thus, the calculations for healing times might have been inaccurate. In contrast, in the present study, the last drain was removed during postoperative hospitalization in all cases. Thus, our study approach ensured that the POPF healing time was closely monitored after the DP.

To our knowledge, the present study was the first to examine the clinical impact of inflammatory and nutritional statuses on the POPF healing time after DP. In the study by Andrianello et al, the WILEY- AGSurg Annals of Gastroenterological Surgery

only factor investigated related to the inflammatory or nutritional status was the albumin level. Thus, the relationship between the POPF healing time and the inflammatory and nutritional status had not been investigated thoroughly.

To assess the clinical relevance of the results from our study, it is important to consider whether clinical advantages could be obtained from a shortened POPF healing time after DP. We considered that a shortened POPF healing time provided three definite clinical advantages. First, a shorter healing time could reduce the risk of postoperative complications secondary to POPF, such as intra-abdominal abscesses, pseudoaneurysms associated with post-pancreatectomy hemorrhage, and postoperative mortality. Second, a shorter healing time could reduce the cost of POPF treatments. Third, a shorter POPF healing time could reduce the delay in starting postoperative adjuvant therapy in patients with pancreatic cancer, where adjuvant chemotherapy is strongly recommended, due to the postoperative prognosis.²⁶⁻²⁸

Taken together, our findings suggested that these advantages might potentially be gained by improving the inflammatory and nutritional status in patients that develop POPF. Indeed, previous studies showed that improving the nutritional status could reduce the incidence of POPF.^{5,29,30} Therefore, comprehensively improving nutritional status might be important for both the prevention and healing of POPF. This hypothesis requires prospective validation in future studies.

The present study had some limitations. First, as mentioned above, it remains unclear why the NLR was significantly associated with the POPF healing time in cases after DP. Clarifying the mechanism underlying the shorter POPF healing time in the NLR ≤2.1 group would help improve the surgical outcomes of DP. Second, we did not clarify the reason for the inconsistency that NLR was significantly associated with the POPF healing time, but there was no significant relationship between the POPF healing time and the other factors potentially associated with the inflammatory or nutritional status. This may be caused by the small-scale patient cohort. A potential explanation for the lack of a relationship between the platelet count and the POPF healing time might be that the platelet counts were influenced by splenic function. Indeed, splenic function was affected by the diseases that were treated with DP. Lastly, our analysis for the identification of factors significantly determining the healing time was performed only with preoperative factors, not intraoperative factors, in order to establish a predictive model with preoperative factors. Actually, we confirmed that several intraoperative factors were insignificant, but considering a possibility that influential factors exist among other intraoperative factors, our results should be validated with other investigations using more intraoperative factors in the future.

In summary, we showed that the POPF healing time after DP was significantly associated with the NLR. The NLR is one of several factors that reflect a patient's inflammatory and nutritional status. These findings suggested that improving patients' inflammatory and nutritional status might shorten the healing time of POPF that occurs after DP.

DISCLOSURE

Conflict of Interest: Authors had no conflict of interests for this article.

Ethical Approval: This study has a retrospective design and is approved by the Institutional Ethics Review Committee (Certificate Number 20466). After an extensive dialogue with the Institutional Ethics Review Committee, patient consent for participation was obtained through an opt-out method.

ORCID

Shogo Kobayashi (D https://orcid.org/0000-0002-8828-1067 Daisaku Yamada (D https://orcid.org/0000-0002-6702-3800 Hidetoshi Eguchi (D https://orcid.org/0000-0002-2318-1129

REFERENCES

- Kleeff J, Diener MK, Z'Graggen K, Hinz U, Wagner M, Bachmann J, et al. Distal pancreatectomy: risk factors for surgical failure in 302 consecutive cases. Ann Surg. 2007;245(4):573–82.
- Zhang H, Zhu F, Shen M, Tian R, Shi CJ, Wang X, et al. Systematic review and meta-analysis comparing three techniques for pancreatic remnant closure following distal pancreatectomy. Br J Surg. 2015;102(1):4–15.
- Ecker BL, McMillan MT, Allegrini V, Bassi C, Beane JD, Beckman RM, et al. Risk factors and mitigation strategies for pancreatic fistula after distal pancreatectomy: analysis of 2026 resections from the International, Multi-Institutional Distal Pancreatectomy Study Group. Ann Surg. 2019;269(1):143–9.
- Vanbrugghe C, Ronot M, Cauchy F, Hobeika C, Dokmak S, Aussilhou B, et al. Visceral obesity and open passive drainage increase the risk of pancreatic fistula following distal pancreatectomy. J Gastrointest Surg. 2019;23(7):1414–24.
- Jablonska B, Lampe P, Mrowiec S. The influence of nutritional status on the incidence of postoperative complications in patients following distal pancreatectomy. Prz Gastroenterol. 2020;15(1):65–75.
- Eguchi H, Nagano H, Tanemura M, Takeda Y, Marubashi S, Kobayashi S, et al. A thick pancreas is a risk factor for pancreatic fistula after a distal pancreatectomy: selection of the closure technique according to the thickness. Dig Surg. 2011;28(1):50–6.
- Abe T, Yamada D, Asukai K, Hasegawa S, Tomokuni A, Wada H, et al. Decreased CT-number in the pancreatic parenchyma is a reliable imaging biomarker of the presence of malignancies in patients with high-risk intraductal papillary mucinous neoplasm. Pancreatology. 2020;20(3):442–7.
- Tomimaru Y, Tanaka K, Noguchi K, Noura SO, Imamura H, Iwazawa T, et al. Significance of fistulography findings to the healing time of postoperative pancreatic fistula after pancreaticoduodenectomy. Surg Today. 2020;50(6):577–84.
- Tomimaru Y, Noguchi K, Noura S, Imamura H, Iwazawa T, Dono K. Factors affecting healing time of postoperative pancreatic fistula in patients undergoing pancreaticoduodenectomy. Mol Clin Oncol. 2019;10(4):435–40.
- Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017;161(3):584–91.
- 11. Wild T, Rahbarnia A, Kellner M, Sobotka L, Eberlein T. Basics in nutrition and wound healing. Nutrition. 2010;26(9):862–6.
- Abe T, Nakata K, Kibe S, Mori Y, Miyasaka Y, Ohuchida K, et al. Prognostic value of preoperative nutritional and immunological factors in patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2018;25(13):3996-4003.

- Kato Y, Yamada S, Suenaga M, Takami H, Niwa Y, Hayashi M, et al. Impact of the controlling nutritional status score on the prognosis after curative resection of pancreatic ductal adenocarcinoma. Pancreas. 2018;47(7):823–9.
- Takagi K, Domagala P, Polak WG, Buettner S, Ijzermans JNM. The controlling nutritional status score and postoperative complication risk in gastrointestinal and hepatopancreatobiliary surgical oncology: a systematic review and meta-analysis. Ann Nutr Metab. 2019;74(4):303-12.
- Jiang N, Deng JY, Ding XW, Ke B, Liu N, Zhang RP, et al. Prognostic nutritional index predicts postoperative complications and long-term outcomes of gastric cancer. World J Gastroenterol. 2014;20(30):10537-44.
- Funamizu N, Nakabayashi Y, Kurihara K. Lower geriatric nutritional risk index predicts postoperative pancreatic fistula in patients with distal pancreatectomy. Mol Clin Oncol. 2020;12(2):134–7.
- Sierzega M, Niekowal B, Kulig J, Popiela T. Nutritional status affects the rate of pancreatic fistula after distal pancreatectomy: a multivariate analysis of 132 patients. J Am Coll Surg. 2007;205(1):52–9.
- Ben Q, An W, Wang L, Wang W, Yu L, Yuan Y. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma. Pancreas. 2015;44(3):471–7.
- Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89(6):1028–30.
- 20. Jamieson NB, Denley SM, Logue J, MacKenzie DJ, Foulis AK, Dickson EJ, et al. A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2011;18(8):2318–28.
- Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009;197(4):466–72.
- Okano K, Kakinoki K, Yachida S, Izuishi K, Wakabayashi H, Suzuki Y. A simple and safe pancreas transection using a stapling device for a distal pancreatectomy. J Hepatobiliary Pancreat Surg. 2008;15(4):353-8.

- 23. Baum CL, Arpey CJ. Normal cutaneous wound healing: clinical correlation with cellular and molecular event. Dermatol Surg. 2005;31(6):674-86.
- Maruyama Y, Inoue K, Mori K, Goral K, Shimamoto R, Onitsuka T, et al. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as predictors of wound healing failure in head and neck reconstruction. Acta Otolaryngol. 2017;137(1):106–10.
- Andrianello S, Marchegiani G, Bannone E, Vacca P, Esposito A, Casetti L, et al. Predictors of pancreatic fistula healing time after distal pancreatectomy. J Hepatobiliary Pancreat Sci. 2020:1–13.
- Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81.
- 27. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297(3):267–77.
- Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101(6):908–15.
- Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S, Nakao A. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg. 2011;98(2):268–74.
- Sato N, Mori Y, Minagawa N, Tamura T, Shibao K, Higure A, et al. Rapid postoperative reduction in prognostic nutrition index is associated with the development of pancreatic fistula following distal pancreatectomy. Pancreatology. 2014;14(3):216–20.

How to cite this article: Toya K, Tomimaru Y, Kobayashi S, Sasaki K, Iwagami Y, Yamada D, et al. Preoperative neutrophilto-lymphocyte ratio predicts healing time for postoperative pancreatic fistula after distal pancreatectomy. Ann Gastroenterol Surg. 2022;6:169–175. <u>https://doi.org/10.1002/</u> ags3.12510